| Detailed information |
|---|
| CancerLivER ID | 2466 |
| Biomarker | MT1B, MT1E, MT1L, CP, ABCA1, CACNB3, PROS1, CPB2, SERPINC1, LACI, MDK, C6, C9, CD5L, GPR126, IL1RAP, DYRK3, PCDH17, TACSTD1, UAP1, C20orf3, CFL2, FLJ12666, KIAA0843, MRC1, NAT2, MYO1B, SIPL, SRD5A2, USP1, |
| Biomarker Name/Symbol (given in Publication) | 30-genes-signature (MT1B, MT1E, MT1L, CP, ABCA1, CACNB3, PROS1, CPB2, SERPINC1, LACI, MDK, C6, C9, CD5L, GPR126, IL1RAP, DYRK3, PCDH17, TACSTD1, UAP1, C20orf3, CFL2, FLJ12666, KIAA0843, MRC1, NAT2, MYO1B, SIPL, SRD5A2, USP10) |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | 30-genes-signature may acts as candidate markers for diagnosing the early onset of HCC in high-risk populations and validated on independent dataset |
| Experimental Condition | High-risk individuals with cirrhosis v/s patients with HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Differentially expressed (PCDH17, MDK, TACSTD1 Upregulated and rest 27 are Downregulated) in High-risk individuals with cirrhosis v/s patients with HCC |
| Level of significance | p < 0.0003 |
| Source | Tissue |
| PMID | 14768006 |
| Type of Biomarker | Prognostic |
| Pathway | Cellular transporter; Blood coagulation; Immune response; Signaling pathway; Cell adhesion |
| Cohort | Cirrhotic tissue samples obtained from 59 patients with end-stage CLD and tissue samples from 14 patients with HCC with a pool of eight normal tissue samples; CLD samples were obtained from patients with HBV (n = 7) and HCV (n = 11) infection, HHC (n = 3), WD (n = 5), ALD (n = 10), PBC (n = 16), and |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | 83% |
| AUC | NA |
| Disease | High-risk individuals with cirrhosis v/s patients with HCC |
| Year of Publication | 2004 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |